Described herein is a compound of formula (I) ##STR00001##
in the form of any one of its stereoisomers or a mixture thereof, and where the Q group represents a CHCHCH.sub.3 group or a CCCH.sub.3 group. Also described herein is a method of using a compound of formula (I), the method including using the compound of formula (I) as part of a perfuming composition or as part of a perfumed consumer product.

The disclosure relates to a process for continuously producing polyoxymethylene dimethyl ethers at low temperature, pertains to the technical field of polyoxymethylene dimethyl ether preparation processes, and solves the technical problem of continuous production of polyoxymethylene dimethyl ether. A membrane separation element with precisely controlled pores in membrane is used to realize a direct separation of the feedstocks from the catalyst within the reactor, and effectively reduce the permeation resistance of the separation membrane tube. By oppositely switching the flowing direction of liquid reaction materials, the adhesion of the catalyst to the separation membrane tube is inhibited, and some particles stuck in separation membrane tube are removed, which ensures the continuous operation of the reaction process and allows a molecular sieve catalyst to exhibit its advantage of long catalytic life.

Described herein is a compound of formula (I)

##STR00001##

in the form of any one of its stereoisomers or a mixture thereof, and where the Q group represents a CHCHCH.sub.3 group or a CCCH.sub.3 group. Also described herein is a method of using a compound of formula (I), the method including using the compound of formula (I) as part of a perfuming composition or as part of a perfumed consumer product.

The object of the present invention is to provide a process for preparing a 5-alken-1-yne compound efficiently at low costs and a process for preparing (2E,6Z)-2,6-nonadienal by making use of the aforesaid process for preparing the 5-alken-1-yne compound. There is provided a process for preparing a 5-alken-1-yne compound of the following formula (4): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2CCH (4) in which Y in formula (4) represents a hydrogen atom or a hydroxyl group, the process comprising at least steps of: subjecting (i) an alkenylmagnesium halide compound prepared from a haloalkene compound of the following formula (1): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2X.sup.1 (1) and (ii) an alkyne compound of the following formula (2): X.sup.2CCSi(R.sup.3)(R.sup.4)(R.sup.5) (2) to a coupling reaction to form a silane compound of the following formula (3): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2CCSi(R.sup.3)(R.sup.4)(R.sup.5) (3); and subjecting the silane compound (3) to a desilylation reaction to form the 5-alken-1-yne compound (4).

The object of the present invention is to provide a process for preparing a 5-alken-1-yne compound efficiently at low costs and a process for preparing (2E,6Z)-2,6-nonadienal by making use of the aforesaid process for preparing the 5-alken-1-yne compound. There is provided a process for preparing a 5-alken-1-yne compound of the following formula (4): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2CCH (4) in which Y in formula (4) represents a hydrogen atom or a hydroxyl group, the process comprising at least steps of: subjecting (i) an alkenylmagnesium halide compound prepared from a haloalkene compound of the following formula (1): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2X.sup.1 (1) and (ii) an alkyne compound of the following formula (2): X.sup.2CCSi(R.sup.3)(R.sup.4)(R.sup.5) (2) to a coupling reaction to form a silane compound of the following formula (3): YZCR.sup.1CR.sup.2(CH.sub.2).sub.2CCSi(R.sup.3)(R.sup.4)(R.sup.5) (3); and subjecting the silane compound (3) to a desilylation reaction to form the 5-alken-1-yne compound (4).

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I).

##STR00001##

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I).

##STR00001##

Provided herein are convenient and efficient processes for preparing (2E,6Z)-2,6-nonadienal and (2E)-6,7-epoxy-2-nonenal with a reduced number of steps. For instance, provided herein is a process for preparing (2E,6Z)-2,6-nonadienal, including at least steps of subjecting a (6,6-dialkoxy-4-hexenylidene)triarylphosphorane compound of the general formula: Ar.sub.3PCH(CH.sub.2).sub.2CHCHCH(OR.sup.1)(OR.sup.2) to a Witting reaction with propanal to form a 1,1-dialkoxy-(6Z)-2,6-nonadiene compound of the general formula (6); and subjecting the 1,1-dialkoxy-(6Z)-2,6-nonadiene compound to hydrolysis to form (2E,6Z)-2,6-nonadienal. Also provided is a process for preparing (2E)-cis-6,7-epoxy-2-nonenal of the formula (8), comprising a step of subjecting (2E,6Z)-2,6-nonadienal thus obtained to epoxidation to form (2E)-cis-6,7-epoxy-2-nonenal. ##STR00001##

Provided herein are convenient and efficient processes for preparing (2E,6Z)-2,6-nonadienal and (2E)-6,7-epoxy-2-nonenal with a reduced number of steps. For instance, provided herein is a process for preparing (2E,6Z)-2,6-nonadienal, including at least steps of subjecting a (6,6-dialkoxy-4-hexenylidene)triarylphosphorane compound of the general formula: Ar.sub.3PCH(CH.sub.2).sub.2CHCHCH(OR.sup.1)(OR.sup.2) to a Witting reaction with propanal to form a 1,1-dialkoxy-(6Z)-2,6-nonadiene compound of the general formula (6); and subjecting the 1,1-dialkoxy-(6Z)-2,6-nonadiene compound to hydrolysis to form (2E,6Z)-2,6-nonadienal. Also provided is a process for preparing (2E)-cis-6,7-epoxy-2-nonenal of the formula (8), comprising a step of subjecting (2E,6Z)-2,6-nonadienal thus obtained to epoxidation to form (2E)-cis-6,7-epoxy-2-nonenal. ##STR00001##

An efficient process for preparing (9E,11Z)-9,11-hexadecadienal of formula (4) ##STR00001##
is provided. The process includes at least steps of: conducting a nucleophilic substitution reaction between an (8E,10Z)-8,10-pentadecadienyl magnesium halide derived from an (8E,10Z)-1-halo-8,10-pentadecadiene of (1): ##STR00002##
and an orthoformate ester (2) ##STR00003##
to thereby prepare a (9E, 11Z)-1,1-dialkoxy-9, 11-hexadecadiene (3): ##STR00004##
and hydrolyzing the (9E, 11Z)-1,1-dialkoxy-9,11-hexadecadiene (3) to obtain (9E, 11Z)-9,11-hexadecadienal (4).